Sanofi

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Sanofi
Lantus
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Fierce Pharma
Sanofi
Provention Bio
M&A
diabetes
Flag link:
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Fierce Pharma
Eli Lilly
Novo Nordisk
Sanofi
insulin
Bernie Sanders
drug pricing
Flag link:
Sanofi’s clinical trial of hemophilia A therapy in children meets endpoint
Sanofi’s clinical trial of hemophilia A therapy in children meets endpoint
Clinical Trials Arena
Sanofi
clinical trials
hemophilia A
Altuviiio
Flag link:
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Yahoo/Benzinga
Regeneron
Sanofi
FDA
Kevzara
Sarilumab
polymyalgia rheumatica
Flag link:
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Fierce Biotech
Junshi Biosciences
Amgen
Sanofi
China
clinical trials
PCSK9 inhibitors
Flag link:
FDA approves Sanofi’s long-lasting hemophilia drug
FDA approves Sanofi’s long-lasting hemophilia drug
BioPharma Dive
Sanofi
FDA
hemophilia A
Altuviiio
Flag link:
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Fierce Pharma
Pfizer
RSV
vaccines
GSK
AstraZeneca
Sanofi
RSVpreF
Flag link:
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
Forbes
RSV
vaccines
GSK
Pfizer
Sanofi
Sobi
Moderna Therapeutics
AstraZeneca
JNJ
FDA
Flag link:
Sanofi and Regeneron face a high-risk test for Dupixent
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case
US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case
Endpoints
Pfizer
Viatris
Sanofi
Regeneron
patents
Supreme Court
Flag link:
Reed relinquishes R&D reins at Sanofi to pursue new opportunity, sparking race to find successor
Reed relinquishes R&D reins at Sanofi to pursue new opportunity, sparking race to find successor
Fierce Biotech
R&D
Sanofi
John Reed
Flag link:
Dupixent kicks off 2023 as top pharma brand for ad impressions
Dupixent kicks off 2023 as top pharma brand for ad impressions
Medical Devices and Diagnostics Industry
Sanofi
Dupixent
asthma
pharma advertising
Flag link:
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Fierce Pharma
Sanofi
Dupixent
earnings
Flag link:
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
BioSpace
Sanofi
tolebrutinib
myasthenia gravis
Flag link:
New competitors push Sanofi to offer voluntary retirement packages at two Indian sites
New competitors push Sanofi to offer voluntary retirement packages at two Indian sites
Endpoints
Sanofi
India
drug manufacturing
Flag link:

Pages